SG Americas Securities LLC Acquires Shares of 10,428 AnaptysBio, Inc. $ANAB

SG Americas Securities LLC acquired a new stake in AnaptysBio, Inc. (NASDAQ:ANAB) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 10,428 shares of the biotechnology company’s stock, valued at approximately $506,000.

Other institutional investors also recently bought and sold shares of the company. Larson Financial Group LLC increased its stake in AnaptysBio by 54.6% in the 3rd quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after buying an additional 473 shares during the period. Bessemer Group Inc. grew its stake in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock worth $44,000 after purchasing an additional 1,292 shares during the period. Tower Research Capital LLC TRC grew its stake in shares of AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 1,377 shares during the period. Osaic Holdings Inc. grew its stake in shares of AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after purchasing an additional 2,326 shares during the period. Finally, Covestor Ltd grew its stake in shares of AnaptysBio by 131,540.0% during the 3rd quarter. Covestor Ltd now owns 6,582 shares of the biotechnology company’s stock worth $201,000 after purchasing an additional 6,577 shares during the period.

Analyst Ratings Changes

ANAB has been the topic of a number of recent analyst reports. Wall Street Zen cut shares of AnaptysBio from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Barclays upped their price target on shares of AnaptysBio from $78.00 to $79.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 4th. UBS Group upped their price target on shares of AnaptysBio from $70.00 to $90.00 and gave the stock a “buy” rating in a research note on Tuesday, March 17th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research note on Wednesday, January 21st. Finally, Wedbush increased their price objective on shares of AnaptysBio from $60.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday, March 12th. Nine analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, AnaptysBio has an average rating of “Moderate Buy” and a consensus price target of $80.10.

AnaptysBio Stock Performance

Shares of NASDAQ ANAB opened at $70.10 on Monday. The stock has a market cap of $2.02 billion, a price-to-earnings ratio of -134.81 and a beta of 0.40. AnaptysBio, Inc. has a 52 week low of $16.03 and a 52 week high of $70.11. The company’s 50-day moving average price is $58.07 and its 200 day moving average price is $46.60.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, March 3rd. The biotechnology company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $0.89 by $0.69. The firm had revenue of $108.25 million for the quarter, compared to analysts’ expectations of $87.09 million. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. As a group, research analysts expect that AnaptysBio, Inc. will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has initiated a share buyback plan on Friday, March 27th that permits the company to repurchase $100,000.00 billion in outstanding shares. This repurchase authorization permits the biotechnology company to purchase up to 5,352,316.2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s management believes its shares are undervalued.

Insider Buying and Selling at AnaptysBio

In other AnaptysBio news, insider Eric J. Loumeau sold 10,000 shares of the company’s stock in a transaction dated Wednesday, February 11th. The shares were sold at an average price of $54.00, for a total value of $540,000.00. Following the transaction, the insider directly owned 12,835 shares in the company, valued at approximately $693,090. This represents a 43.79% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John P. Schmid sold 20,645 shares of the company’s stock in a transaction dated Monday, March 30th. The shares were sold at an average price of $56.11, for a total transaction of $1,158,390.95. Following the completion of the transaction, the director owned 31,622 shares in the company, valued at approximately $1,774,310.42. This trade represents a 39.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 59,324 shares of company stock valued at $3,318,124 in the last quarter. Insiders own 33.50% of the company’s stock.

AnaptysBio Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.